Pharmafile Logo

Solupore

- PMLiVE

IMV preps pivotal trials for ovarian cancer T cell therapy

Drug stabilised disease in 79% of 19 evaluable patients

- PMLiVE

GSK pays $50m upfront to tap Immatics’ cell therapy platform

Deal focuses on T cell receptor therapies

- PMLiVE

CRISPR gene-editing in cancer patients is safe, according to new study

Patients had no side effects following CRISPR treatment

- PMLiVE

Newly-listed BioNTech buys Neon to boost cell therapy assets

German biotech has agreed to pay $67m in the deal

- PMLiVE

Bluebird bio launches beta thalassaemia gene therapy Zynteglo in Germany

Will offer treatment via an outcomes-based payment model

- PMLiVE

Bluebird bio’s sickle cell gene therapy shows early-study benefit

Closely follows approval of beta thalassaemia therapy Zynteglo

- PMLiVE

Five key trends in precision and personalised healthcare

Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...

Blue Latitude Health

- PMLiVE

Astellas makes gene therapy a core focus with $3bn Audentes buy

Deal includes a late-stage candidate for a rare disease

- PMLiVE

Private equity firm backs Ferring gene therapy venture

Joint venture will focus on development of therapies for bladder cancer

- PMLiVE

Vertex reveals promising data from first CRISPR-treated patients

Investigational gene therapy has potentially curative effect

- PMLiVE

Solid Bio falls as FDA halts DMD trial over safety concerns

Shares in the biotech dropped dramatically following the announcement

- PMLiVE

Precision medicine at Blue Latitude Health

At Blue Latitude Health we have identified 90+ insights about commercialising precision medicines. Check out our video to get a run down on three core components of the commercialisation and...

Blue Latitude Health

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links